Skip to main content
. 2019 Nov 26;10(12):888. doi: 10.1038/s41419-019-2112-1

Fig. 2. PGK1 silencing protects human osteoblasts from DEX-induced death and apoptosis.

Fig. 2

Stable OB-6 osteoblastic cells (a–f) or primary human osteoblasts (g–i) with applied PGK1 shRNA (“sh-PGK1-S1/S2”) or the non-sense control shRNA (“sh-C”) were treated with or without DEX (1 μM) for applied time periods, cell viability (MTT assay; a and g) and cell death (LDH medium release; b and h) were tested; Cell apoptosis activation was tested by the listed assays (c–f, i). Expression of listed proteins was quantified, normalized to the loading control (d). Data were expressed as mean ± standard deviation (SD, n = 5). “Ctrl” represents untreated control group (Same for all Figures). *p < 0.05 vs. “sh-C” cells with “Ctrl” treatment. #p < 0.05 vs. “sh-C” cells with DEX treatment. Experiments in this figure were repeated four times, and similar results were obtained.